Brokerages Set Omeros Co. (NASDAQ:OMER) Price Target at $22.50

Shares of Omeros Co. (NASDAQ:OMER - Get Free Report) have earned an average rating of "Moderate Buy" from the five analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $22.50.

OMER has been the subject of several recent analyst reports. D. Boral Capital restated a "buy" rating and issued a $36.00 price target on shares of Omeros in a report on Thursday, January 16th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Omeros in a research report on Thursday, November 14th. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research report on Friday, January 17th. Rodman & Renshaw started coverage on Omeros in a research report on Thursday, November 14th. They set a "buy" rating and a $9.00 price objective for the company. Finally, RODMAN&RENSHAW raised Omeros to a "strong-buy" rating in a research report on Thursday, November 14th.

Omeros Price Performance

Shares of Omeros stock traded up $0.06 during trading hours on Tuesday, hitting $9.18. The company's stock had a trading volume of 425,131 shares, compared to its average volume of 508,528. Omeros has a 12 month low of $2.61 and a 12 month high of $13.60. The stock has a 50 day moving average of $9.36 and a 200 day moving average of $6.57. The company has a market capitalization of $531.98 million, a PE ratio of -3.97 and a beta of 1.98.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of OMER. Truvestments Capital LLC lifted its position in shares of Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 1,972 shares during the period. Quantbot Technologies LP bought a new position in shares of Omeros during the fourth quarter worth approximately $46,000. Picton Mahoney Asset Management increased its stake in shares of Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 4,404 shares during the period. Finally, US Bancorp DE bought a new position in shares of Omeros during the fourth quarter worth approximately $81,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.